Scientific Poster Session III - Original Research

Original Research
  Monday, November 13, 2023
  01:00 PM–02:30 PM

Abstract

Introduction:

The ongoing COVID-19 pandemic has posed increased risks of hospitalization and mortality in patients with underlying chronic kidney disease (CKD).

Research Question or Hypothesis: Current data on vaccine effectiveness (VE) of COVID-19 vaccines are limited to priming doses in patients with CKD on dialysis and seroconversion in the non-dialysis population.

Study Design: Case-control study in adults with CKD using data extracted from the electronic health record database in Hong Kong.

Methods:

Adults with CKD and COVID-19 confirmed by polymerase chain reaction were included in the study. Each case was matched with up to 10 controls based on age, gender, and index date (within 3 calendar days). The VE of BNT162b2 and CoronaVac in preventing COVID-19 infection, hospitalizations, and mortality was estimated using conditional logistic regression adjusted by patients’ comorbidities and medication history during the outbreak from January to March 2022.

Results:

A total of 20,570 COVID-19 cases, 6,604 COVID-19-related hospitalizations, and 2,267 COVID-19-related mortality were matched to 81,092, 62,803, and 21,348 controls, respectively. Compared to the unvaccinated group, three doses of BNT162b2 or CoronaVac were associated with a reduced risk of infection [VE: BNT162b2: 64.6% (95% CI: 61.2 – 67.7), CoronaVac: 43.8% (95% CI: 39.4 – 47.8)], hospitalization [VE: BNT162b2: 82.5% (95% CI: 78.2 – 85.9), CoronaVac: 80.8% (76.7 – 84.2)], and mortality [VE: BNT162b2: 95.4% (95% CI: 90.1 – 97.8), CoronaVac: 94.0% (95% CI: 89.5 – 96.6)]. Much higher effectiveness was shown in vaccine recipients who received three doses of BNT162b2 and CoronaVac, compared to two-dose and one-dose recipients.

Conclusion:

A dose-response relationship was observed between the number of BNT162b2 or CoronaVac doses administered and the effectiveness against COVID-19 infection and severe COVID-19 diseases during the Omicron BA.2 pandemic in the CKD population.

Presenting Author

Franco WT Cheng MClinPharm
The University of Hong Kong

Authors

Francisco TT Lai PhD
The University of Hong Kong

Xue Li PhD
The University of Hong Kong

Cheyenne IY Chan MPsyMed
The University of Hong Kong

Esther W.Y. Chan BPharm(Hons), MClinPharm, PhD, GradCertPharmEc
University of Hong Kong

Celine SL Chui PhD
The University of Hong Kong

Sydney CW Tang PhD
The University of Hong Kong

Eric YF Wan PhD
The University of Hong Kong

Boyuan Wang MPH
The University of Hong Kong

Carlos KH Wong PhD
The University of Hong Kong

Ian CK Wong PhD
The University of Hong Kong

Vincent KC Yan BPharm
The University of Hong Kong